Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.20 Per Share

Equities analysts expect that Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) will announce earnings per share of ($0.20) for the current quarter, Zacks reports. Three analysts have issued estimates for Spectrum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.24). Spectrum Pharmaceuticals reported earnings of ($0.05) per share in the same quarter last year, which would indicate a negative year over year growth rate of 300%. The firm is expected to announce its next earnings report on Thursday, May 4th.

On average, analysts expect that Spectrum Pharmaceuticals will report full year earnings of ($0.79) per share for the current year, with EPS estimates ranging from ($0.98) to ($0.58). For the next year, analysts forecast that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.78) to $0.05. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings data on Wednesday, March 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. The company earned $35.24 million during the quarter, compared to analysts’ expectations of $31.13 million. Spectrum Pharmaceuticals had a negative net margin of 34.19% and a negative return on equity of 13.92%. The firm’s revenue for the quarter was down 30.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.02) EPS.

Several analysts have recently weighed in on the stock. FBR & Co reiterated a “buy” rating on shares of Spectrum Pharmaceuticals in a research report on Saturday, April 1st. HC Wainwright set a $10.00 target price on shares of Spectrum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, March 11th. Jefferies Group LLC assumed coverage on shares of Spectrum Pharmaceuticals in a research report on Friday, February 10th. They set a “buy” rating and a $8.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.80.

TRADEMARK VIOLATION NOTICE: “Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.20 Per Share” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/04/21/spectrum-pharmaceuticals-inc-sppi-expected-to-post-earnings-of-0-20-per-share.html.

Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up 1.72% during trading on Tuesday, reaching $7.09. 1,464,754 shares of the company’s stock were exchanged. The company’s market capitalization is $555.25 million. The company’s 50-day moving average is $6.42 and its 200-day moving average is $5.03. Spectrum Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $7.74.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors raised its position in Spectrum Pharmaceuticals by 24.1% in the third quarter. BlackRock Fund Advisors now owns 7,417,828 shares of the biotechnology company’s stock worth $34,641,000 after buying an additional 1,439,851 shares during the period. Dimensional Fund Advisors LP raised its position in Spectrum Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,970,631 shares of the biotechnology company’s stock worth $8,730,000 after buying an additional 181,018 shares during the period. Macquarie Group Ltd. raised its position in Spectrum Pharmaceuticals by 4.0% in the fourth quarter. Macquarie Group Ltd. now owns 1,800,669 shares of the biotechnology company’s stock worth $7,977,000 after buying an additional 69,087 shares during the period. Teachers Advisors LLC raised its position in Spectrum Pharmaceuticals by 1.4% in the fourth quarter. Teachers Advisors LLC now owns 1,098,002 shares of the biotechnology company’s stock worth $4,864,000 after buying an additional 15,197 shares during the period. Finally, Alambic Investment Management L.P. raised its position in Spectrum Pharmaceuticals by 50.8% in the third quarter. Alambic Investment Management L.P. now owns 295,601 shares of the biotechnology company’s stock worth $1,380,000 after buying an additional 99,600 shares during the period. Hedge funds and other institutional investors own 69.31% of the company’s stock.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

5 Day Chart for NASDAQ:SPPI

Get a free copy of the Zacks research report on Spectrum Pharmaceuticals (SPPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply